Man Group’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Man Group’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-14,025	Closed	-$44K	–	1861
2020 Q1	$44K	Buy	+14,025	New	+$51.7K	﹤0.01%	1553
2018 Q4	–	Sell	-207,303	Closed	-$2.01M	–	2168
2018 Q3	$2.01M	Sell	207,303 -268,078	-56%	-$2.7M	0.01%	1420
2018 Q2	$4.85M	Sell	475,381 -71,442	-13%	-$808K	0.02%	963
2018 Q1	$7.11M	Buy	+546,823	New	+$8.14M	0.03%	649

Other funds holding PRTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Man Group's PRTK Position: Q2 2020 in Review

Man Group sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2020, closing a stake of 14,025 shares — an estimated $44K sold.

Man Group first reported a position in PRTK in Q1 2018 and held it in 4 quarters. The position peaked at $7.11M in Q1 2018. 99 funds tracked by Wall St. Rank hold PRTK as of Q2 2020.

Man Group reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
Man Group sold 14,025 Paratek Pharmaceuticals, Inc. shares in Q2 2020, an estimated $44K.
Man Group first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2018 and held it in 4 quarters.
Man Group's Paratek Pharmaceuticals, Inc. position peaked at $7.11M in Q1 2018.
99 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2020.

Based on Man Group's 13F filing for Q2 2020, filed 14 Aug 2020.